文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The Use of Proton Pump Inhibitors in Patients with Liver Cirrhosis: Real Life Experience.

作者信息

Eftimie Spitz Raphaël, Popa Stefan Lucian, Grad Simona, Dumitrascu Dan Lucian, Ismaiel Abdulrahman, Surdea-Blaga Teodora

机构信息

Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania.

2nd Department of Internal Medicine, Emergency County Hospital, 400003 Cluj-Napoca, Romania.

出版信息

J Clin Med. 2024 Aug 30;13(17):5155. doi: 10.3390/jcm13175155.


DOI:10.3390/jcm13175155
PMID:39274368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11396469/
Abstract

(1) : Proton pump inhibitors (PPIs) are commonly prescribed for gastric disorders. In patients with liver cirrhosis, PPI use is associated with an increased risk of spontaneous bacterial peritonitis and increased mortality rates; therefore, they should be used with caution. This study aims to evaluate the appropriateness of PPI prescriptions in hospitalized cirrhotic patients against current clinical guidelines to identify patterns of misuse and guide better prescribing practices. (2) : A retrospective study was conducted on liver cirrhosis inpatients in an internal medicine department from January 2022 to May 2023. The primary measure was the proportion of PPI prescriptions aligned with clinical guidelines. Medical files were entirely reviewed by researchers to assess the appropriateness of PPI prescriptions using the current guidelines. Outcomes included the identification of common reasons for PPI prescription and the rate of inappropriate PPI use among the study population. (3) : The study included 189 cirrhotic patients, with PPIs prescribed to 95 (50.2%) patients during hospitalization and 75 (39.7%) patients at discharge. Among those, 47.4% of the inpatients and 34.7% at discharge had no valid indication for PPI administration. The most common reason for PPI prescription during hospital stays was gastritis, followed by antiplatelet use in high-risk patients, ulcers, and upper gastrointestinal bleeding. The most common inappropriate indication was portal hypertensive gastropathy (PHG), followed by treatment with corticosteroids and anticoagulants alone. We did not find an association between PPI administration during hospital stays and infections. Only in 4% of cases patients should have received PPIs and did not. (4) : There is a concerning overprescription of PPIs in cirrhotic patients, often deviating from established guidelines. It subjects patients to unnecessary risks. There is an urgent need for increased awareness and adherence to clinical guidelines regarding PPI prescriptions in cirrhotic patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/96c30ffbfd17/jcm-13-05155-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/ddf68d72b231/jcm-13-05155-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/ad3746043f35/jcm-13-05155-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/22804eed330a/jcm-13-05155-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/d36677b7e9cf/jcm-13-05155-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/d55a40fd7c02/jcm-13-05155-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/96c30ffbfd17/jcm-13-05155-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/ddf68d72b231/jcm-13-05155-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/ad3746043f35/jcm-13-05155-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/22804eed330a/jcm-13-05155-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/d36677b7e9cf/jcm-13-05155-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/d55a40fd7c02/jcm-13-05155-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b9c/11396469/96c30ffbfd17/jcm-13-05155-g006.jpg

相似文献

[1]
The Use of Proton Pump Inhibitors in Patients with Liver Cirrhosis: Real Life Experience.

J Clin Med. 2024-8-30

[2]
Proton Pump Inhibitors Use and Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Retrospective Cohort Analysis.

Gastroenterology Res. 2022-8

[3]
Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice.

Arch Intern Med. 2010-5-10

[4]
Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study.

Int J Gen Med. 2023-1-11

[5]
Inappropriate Prescription of Proton Pump Inhibitors in a Community Setting.

Can J Hosp Pharm. 2018

[6]
Proton pump inhibitors: Are we still prescribing them without valid indications?

Australas Med J. 2014-11-30

[7]
[Impact of an evaluation of the professional practices on the relevance of proton pump inhibitors prescriptions pertinence at the hospital].

Rev Med Interne. 2018-8

[8]
The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.

Int J Clin Pharm. 2015-12

[9]
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.

Trials. 2022-4-12

[10]
Prescribing Patterns of Proton Pump Inhibitors in Germany: A Retrospective Study Including 472 146 Patients.

J Prim Care Community Health. 2023

引用本文的文献

[1]
Use of Proton Pump Inhibitors Among Patients With Alcohol-Related Cirrhosis-A Danish Nationwide Cohort Study.

Liver Int. 2025-4

本文引用的文献

[1]
Inappropriate use of proton pump inhibitors in clinical practice globally: a systematic review and meta-analysis.

Gut. 2024-12-10

[2]
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.

Am J Health Syst Pharm. 2023-4-8

[3]
Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis.

Aliment Pharmacol Ther. 2023-1

[4]
SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS.

Arq Gastroenterol. 2022

[5]
Appropriateness and Associated Factors of Stress Ulcer Prophylaxis for Surgical Inpatients of Orthopedics Department in a Tertiary Hospital: A Cross-Sectional Study.

Front Pharmacol. 2022-6-2

[6]
Effects of Proton Pump Inhibitors in Cirrhotic Patients: What Do We Really Know?

Gastroenterology. 2022-7

[7]
The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study.

Gastroenterology. 2022-7

[8]
Correlation Between Proton Pump Inhibitors and the Complications of Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Turk J Gastroenterol. 2022-1

[9]
Liver Disease: Cirrhosis.

FP Essent. 2021-12

[10]
Liver cirrhosis.

Lancet. 2021-10-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索